Antibody Drug Design
Antibody drug design is a pivotal discipline in contemporary biomedicine, particularly for the treatment of cancers, autoimmune disorders, and infectious diseases. Monoclonal antibodies have demonstrated remarkable therapeutic success across a broad spectrum of indications. Conventional antibody design relies on extensive laboratory work and animal studies, making the process both time-intensive and resource-intensive.
ICDMO provides comprehensive AI-driven antibody drug design services. Our state-of-the-art deep learning models accurately predict antibody structures, optimise binding affinity and target specificity, and forecast in vivo biological efficacy — enabling clients to develop highly effective antibody therapeutics with greater speed. Every computational stage is complemented by wet laboratory validation, ensuring thoroughness, reducing risk, and materially improving overall success rates.
We support antibody drug design through two methods:
Library Screening Based on Embedding Large Models
Our sequence library screening service integrates a broad range of cutting-edge computational architectures, including LSTM (Long Short-Term Memory networks), Transformers, BERT (Bidirectional Encoder Representations from Transformers), Variational Autoencoders (VAEs), and Generative Adversarial Networks (GANs). By applying these models for deep optimisation and self-supervised learning, we achieve substantial improvements in prediction accuracy through precise sequence generation and intelligent candidate prioritisation.
Figure 1. The overall workflow for our proposed sequence generation and prioritisation scheme is based on LSTM.
By choosing our service, you receive a fully integrated, end-to-end antibody development solution encompassing sequence design, library construction, systematic screening, and experimental validation. This all-inclusive approach dramatically increases research and development efficiency and success rates while simultaneously reducing development costs and de-risking each programme milestone.
1
Library Construction
Antibody samples are collected from specific sources such as human immune libraries or B cells, transcribed into cDNA, and inserted into expression vectors to construct a high-diversity antibody display library.
2
Screening
The antibody display library is exposed to immobilised target antigens. Through multiple rounds of panning under progressively stringent conditions, antibodies with specific binding to the target antigen are significantly enriched.
3
Selection and Characterisation
Binding-positive antibody clones are selected and subjected to sequence analysis and biophysical characterisation using SPR or ELISA to identify candidates with optimal affinity, specificity, and developability profiles.
4
Wet Lab Validation
Beyond computational sequence generation, we provide full experimental validation to confirm that selected antibodies function as intended, exhibit the required stability, and meet pre-defined performance benchmarks.
Target-Based de novo Design
Lead optimisation and de novo design are the two central pillars of our AI-driven antibody development service. By leveraging generative AI models, we enable zero-shot design of antibody CDRs for specific targets, screening large variant libraries to identify sequences with optimal binding affinity. Our models have demonstrated high effectiveness in designing all CDRs of the antibody heavy chain, as confirmed by SPR characterisation. In addition, our high-throughput screening assay — validated against SPR data — generates quantitative binding affinity scores for large panels of antibody variants. Large language models trained on this data can predict binding affinities for novel, unseen variants, directly enabling the development of antibodies with substantially improved characteristics. Our service takes a holistic approach by simultaneously co-optimising multiple properties, thereby accelerating and de-risking the entire antibody drug development process.
Figure 2. Deep learning models trained on antibody–antigen interactions, complemented by high-throughput experiments, can design antibodies that bind to antigens unseen by the models without requiring further affinity optimisation. (Shanehsazzadeh, A., et al., 2024)
1
Database Integration
Curate and consolidate relevant data from major biological and structural databases, ensuring comprehensive and high-quality input for all AI models.
2
Target Analysis
Perform in-depth analysis of target proteins to characterise their structural and functional properties, providing the foundation for precise AI-guided predictions and optimisations.
3
Algorithm Selection
Select the most appropriate machine learning and AI algorithms — from geometric deep learning to transformer-based architectures — based on the specific demands of each antibody design project.
4
Sequence Generation
Generate and iteratively refine antibody sequences using advanced generative AI techniques, ensuring each candidate meets target binding specifications and exhibits optimal in silico performance.
Advantages of Our Antibody Drug Design Service
Advanced Deep Learning Algorithms
Deliver precise improvements in binding affinity and target specificity through state-of-the-art sequence modelling.
High-Throughput Screening
Rapidly identify the highest-confidence candidates from millions of computationally evaluated variants.
Robust Wet Lab Validation
Guarantee functional stability and real-world effectiveness through integrated experimental confirmation at every stage.
Partnering with ICDMO for your antibody drug development programme delivers reduced costs, accelerated timelines, and meaningfully improved success rates. Contact our team today to advance your research and development initiatives with our comprehensive, AI-first solutions.
* For research use only. Not intended for any clinical use.
Is This the Right Service for You?
Choose this when
An antibody lead needs sequence engineering before expression resources are committed
Developability liabilities must be removed without disturbing the paratope
A designed panel is wanted rather than a single construct
Consider another service when
Structural modelling alone is what is needed
Antibody Structure Prediction & Optimization The format is single-domain
VHH Antibody AI Screening & Validation What Goes Wrong, and How We Handle It
These are the failure modes that produce confident-looking results which do not survive the next experiment. Each one is designed against rather than discovered afterwards.
Sequence-level design without a structural model of the paratope
Variable domains and, where possible, the antigen complex are modelled before any substitution is proposed.
Liability removal that quietly costs binding
Every substitution is scored for binding and stability, and the expected cost is reported per design.
De novo binder design scoped as though it were reliable
It is scoped as exploratory with expected hit rates stated; engineering an existing binder is presented as the dependable route.
A Worked Example
A panel that separated three hypotheses
The situation
The lead had an oxidation-prone methionine in CDR-H3 and unclear contribution from two framework residues.
What the work involved
The complex was modelled, the interface was decomposed per residue, and a panel was designed in which each construct tested one hypothesis rather than combining them.
What came back
Fourteen constructs whose results were individually interpretable, identifying a methionine replacement that removed the liability while retaining measured affinity.
Illustrative of the shape this work takes. Details are generalised, no client or target is identified, and scope and outcome vary with the system in question.
What Published Work Reports
The results below were published by independent groups and are cited to show what these computational approaches have achieved in the literature. They are not ICDMO project results, and outcomes vary substantially between targets, datasets and programmes. We do not promise comparable results for any particular project.
10- to 140-fold affinity improvements from computational design
Computational interface redesign produced a tenfold affinity improvement in cetuximab, reaching 52 pM, and a 140-fold improvement to 30 pM for an anti-lysozyme model antibody — improvements achieved by designing a small number of interface substitutions rather than by library selection.
Lippow, Wittrup & Tidor, Nature Biotechnology, 2007 ↗Interface models predict which substitutions help, with measurable accuracy
A 2024 study combining structural interface analysis with sequence-derived evolutionary information reported a predictive model for antibody–antigen interaction with an area under the curve of 0.83 and precision of 0.89 on held-out data, and experimentally confirmed a designed point mutation that improved affinity 2.5-fold to 2 nM. Typical computational maturation gains are modest per mutation, which is why a designed panel is measured rather than a single variant.
Experimental validation study, 2024 ↗What We Need From You
▸Antibody sequences (VH and VL, or VHH) with the format and constant regions if already fixed
▸Antigen sequence or structure, with epitope information from mapping or mutagenesis where available
▸Measured data for the parental molecule: affinity, expression titre, thermal stability, aggregation behaviour
▸The required profile: affinity, selectivity, effector function, half-life, format and intended indication
▸How many constructs you can express and characterise, which determines panel size
How the Analysis Is Performed
▸Sequence numbering, germline assignment and CDR definition across standard numbering schemes
▸Variable domain structure prediction and antigen complex modelling where the epitope is known
▸Interface analysis with per-residue energetic decomposition to identify the positions carrying binding
▸Computational mutagenesis scored for both binding and folding stability, since the two frequently oppose one another
▸Developability liability mapping across the whole sequence with mitigation designs proposed
▸Panel construction so that the delivered variants test distinct, separable hypotheses
What You Receive
▸Ranked designed sequences in annotated FASTA with the rationale for every change
▸Structural models of the variable domains and, where the epitope is known, the antigen complex
▸Developability report mapping deamidation, isomerisation, oxidation, glycosylation and charge or hydrophobic patches by position
▸Germline and humanness assessment with predicted immunogenicity risk
▸Recommended expression and testing order, stating which design hypothesis each construct tests
Interpretation and Limitations
Predicted affinity values are not reliable enough to act on without measurement; the useful output is a ranking and a set of flagged risks. De novo binder design against a new antigen remains low-yield and is scoped as exploratory, whereas engineering an existing binder is far more dependable. Expression, aggregation and immunogenicity predictions indicate risk rather than outcome, and all deliverables are for research use only.
Questions We Are Asked Before Scoping
Do you express and test the antibodies?
No. ICDMO is a computational CDMO. We design, model and prioritise; expression, purification and binding characterisation are executed by your team or a partner, and we help plan and interpret that work.
How many designs should we make?
Most programmes express ten to thirty. Because binding and expression outcomes cannot be predicted reliably enough to bet on one sequence, a designed panel that tests separable hypotheses is far more efficient.
What if the antigen structure is unknown?
We predict it, and the resulting complex model carries greater uncertainty. Where the epitope is also unknown, we recommend epitope mapping first, since designing against an unknown interface is largely guesswork.
Quick Inquiry
Fill in the form below and our team will respond with a detailed proposal within one business day.